FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment of adult patients with symptomatic heart failure when ACE-inhibitors are not tolerated or in beta-blocker intolerant patients as add-on therapy to ACE-inhibitors when mineralocorticoid receptor antagonists cannot be used (see sections 4.2, 4.4, 4.5 and 5.1).”
Croatian: Liječenje odraslih bolesnika sa simptomatskim zatajenjem srca kada se ACE inhibitori ne podnose ili u bolesnika s intolerancijom na beta blokatore kao dodatna terapija uz ACE inhibitore kada se antagonisti mineralokortikoidnog receptora ne mogu koristiti (vidjeti dijelove 4.2, 4.4, 4.5 i 5.1).”
English: The following cross-reference should be added to the “Posology in Hypertension” section: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Croatian: “Doziranje kod hipertenzije” potrebno je dodati sljedeću referencu: “(vidjeti dijelove 4.3, 4.4, 4.5 i 5.1)”.
English: Use of these combinations should be under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.
Croatian: Korištenje tih kombinacija treba biti pod nadzorom specijalista i uz pažljivo praćenje bubrežne funkcije, elektrolita i krvnog tlaka.
English: “X can be used to treat adult heart failure patients with reduced heart muscle function when Angiotensin Converting Enzyme (ACE) inhibitors cannot be used or in addition to ACE-inhibitors when symptoms persist despite treatment and mineralocorticoid receptor antagonists (MRA) cannot be used.
Croatian: “X se može koristiti za liječenje odraslih osoba sa zatajenjem srca i smanjenom funkcijom srčanog mišića kada se inhibitori angiotenzin konvertirajućeg enzima (ACE) ne mogu koristiti ili uz ACE inhibitore kada simptomi ustraju usprkos liječenju a ne mogu se koristiti antagonisti mineralokortikoidnog receptora (MRA). (ACE inhibitori i MRA-ovi su lijekovi koji se koriste za liječenje zatajenja srca).”
English: Section 4.2 - Posology and method of administration
Croatian: Dio 4.2 - Doziranje i način primjene
English: In addition, for products authorised in the treatment of heart failure, the existing heart failure indication should be revised as follows:
Croatian: Osim toga, za lijekove koji su odobreni za liječenje zatajenja srca postojeću indikaciju zatajenja srca potrebno je revidirati kako slijedi: “Zatajenje srca
English: “The treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction ≤ 40%) when ACE-inhibitors are not tolerated or as add-on therapy to ACE-inhibitors in patients with symptomatic heart failure, despite optimal therapy, when mineralocorticoid receptor antagonists are not tolerated (see sections 4.2, 4.4, 4.5 and 5.1)”.
Croatian: “Liječenje odraslih bolesnika sa zatajenjem srca i oštećenom sistoličkom funkcijom lijeve klijetke (ejekcijska frakcija lijeve klijetke ≤40%) kada se ACE inhibitori ne podnose ili kao dodatak uz ACE inhibitore u bolesnika sa simptomatskim zatajenjem srca, usprkos optimalnoj terapiji, kada se antagonisti mineralokortikoidnog receptora ne podnose (vidjeti dijelove 4.2, 4.4, 4.5 i 5.1)”.
English: I. Summary of Product Characteristics
Croatian: Sažetak opisa svojstava lijeka
English: In addition, for products authorised in the treatment of heart failure, the following wording should be added in the “Heart failure” section:
Croatian: Osim toga, za lijekove koji su odobreni za liječenje zatajenja srca, tekst u nastavku je potrebno dodati u dio
English: If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.
Croatian: Ako se terapija dvostrukom blokadom smatra apsolutno nužnom, smije se samo provoditi pod nadzorom specijalista i uz pažljivo praćenje bubrežne funkcije, elektrolita i krvnog tlaka.
English: • “if you are taking any of the following medicines used to treat high blood pressure: - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetesrelated kidney problems.
Croatian: • “ako uzimate bilo koji od lijekova navedenih u nastavku, koji se koriste za liječenje visokog krvnog tlaka: - ACE inhibitor (primjerice enalapril, lisinopril, ramipril), osobito ako imate bubrežne tegobe povezane sa šećernom bolešću. - aliskiren
English: • “if you have diabetes mellitus or impaired kidney function and you are treated with either of the following classes of medicines used to treat high blood pressure: - an ACE-inhibitor such as enalapril, lisinopril, ramipril.
Croatian: • “ako imate šećernu bolest ili oštećenu bubrežnu funkciju i liječite se bilo kojom od skupina lijekova navedenih u nastavku, koje se koriste za liječenje visokog krvnog tlaka: - ACE inhibitorom kao što je enalapril, lisinopril, ramipril ili - blokatorom angiotenzin II receptora kao što je valsartan, telmisartan, irbesartan”
English: “Dual blockade of the renin-angiotensin-aldosterone system (RAAS) There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure).
Croatian: “Dvostruka blokada renin-angiotenzin-aldosteronskog sustava (RAAS) Postoje dokazi da istodobna primjena ACE inhibitora, blokatora angiotenzin II receptora ili aliskirena povećava rizik od hipotenzije, hiperkalemije i smanjene bubrežne funkcije (uključujući akutno zatajenje bubrega).
English: Talk to your doctor <or> <pharmacist> <or nurse> before <taking> <using> X
Croatian: <ili medicinskoj sestri> prije nego <uzmete>
English: “The concomitant use of [Product name] with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and
Croatian: “Istodobna primjena [naziv lijeka] s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).”
English: “If you are taking an angiotensin II receptor blocker (ARB) or an ACE-inhibitor, (see also information under the headings “Do not <take> <use> X” and “Warnings and precautions”)”
Croatian: “Ako uzimate blokator angiotenzin II receptora (ARB) ili ACE inhibitor, (vidjeti također informacije pod naslovima “Nemojte <uzimati> <primjenjivati> X” i “Upozorenja i mjere opreza”)”
English: If you are being treated with an ACE-inhibitor together with certain other medicines to treat your heart failure, which are known as mineralocorticoid receptors antagonists (MRA) (for example spironolactone, eplerenone) or betablockers (for example metoprolol).”
Croatian: Ako se liječite ACE inhibitorom zajedno s određenim drugim lijekovima za liječenje zatajenja srca, koji su poznati kao antagonisti mineralokortikoidnih receptora (MRA) (primjerice spironolakton, eplerenon) ili beta blokatorima (primjerice metoprolol).”
English: The following wording should be added to this section:
Croatian: U ovaj dio potrebno je dodati sljedeći tekst:
English: • - if you are being treated with an ACE-inhibitor together with certain other medicines to treat your heart failure, which are known as mineralocorticoid receptors antagonists (MRA) (for example spironolactone, eplerenone) or betablockers (for example metoprolol).
Croatian: • - ako se liječite ACE inhibitorom zajedno s određenim drugim lijekovima za liječenje zatajenja srca, koji se nazivaju antagonistima mineralokortikoidnih receptora (MRA) (primjerice spironolakton, eplerenon) ili beta blokatorima (primjerice metoprolol).
English: ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.”
Croatian: ACE inhibitori i blokatori angiotenzin II receptora ne smiju se istodobno primjenjivati u bolesnika s dijabetičkom nefropatijom.”
English: ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.
Croatian: ACE inhibitori i blokatori angiotenzin II receptora stoga se ne smiju istodobno primjenjivati u bolesnika s dijabetičkom nefropatijom.
English: The following wording should be included in the specified sections:
Croatian: U navedene dijelove potrebno je uključiti sljedeći tekst:
English: The following contraindication should be added to this section: “The concomitant use of [Product name] with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and
Croatian: U ovaj dio potrebno je dodati sljedeću kontraindikaciju: “Istodobna primjena [naziv lijeka] s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).”
English: If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not <take> <use> X” and “Warnings and precautions”)
Croatian: Ako uzimate ACE inhibitor ili aliskiren (vidjeti također informacije pod naslovima “Nemojte <uzimati> <primjenjivati> X” i “Upozorenja i mjere opreza”)”.
English: “Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, stroke, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).”
Croatian: “Podaci iz kliničkih ispitivanja pokazali su da je dvostruka blokada renin-angiotenzin-aldosteronskog sustava (RAAS) kombiniranom primjenom ACE inhibitora, blokatora angiotenzin II receptora ili aliskirena povezana s većom učestalošću štetnih događaja kao što su hipotenzija, hiperkalemija i smanjena bubrežna funkcija (uključujući akutno zatajenje bubrega) u usporedbi s primjenom samo jednog lijeka koji djeluje na RAAS (vidjeti dijelove 4.3, 4.4 i 5.1).”
English: For products containing aliskiren, the existing product information shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below
Croatian: Za lijekove koji sadrže aliskiren, postojeće informacije o lijeku se trebaju izmjeniti (umetanjem, zamjenom ili brisanjem teksta prema potrebi) da odražavaju dogovoreni tekst kao što je predviđeno u nastavku
English: For products containing valsartan, the existing product information shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below
Croatian: Za lijekove koji sadrže valsartan, postojeće informacije o lijeku se trebaju izmjeniti (umetanjem, zamjenom ili brisanjem teksta prema potrebi) da odražavaju dogovoreni tekst kao što je predviđeno u nastavku
English: The following contraindication should be reflected in this section: “The concomitant use of [Product name] with an ACE-inhibitor or an angiotensin II receptor blocker is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.4, 4.5 and 5.1).”
Croatian: U ovom dijelu potrebno je dodati sljedeću kontraindikaciju: “Istodobna primjena [naziv lijeka] s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).”
English: Section 4.4 - Special warnings and precautions for use The following wording should be reflected in this section: “Dual blockade of the renin-angiotensin-aldosterone-system (RAAS) Hypotension, syncope, stroke, hyperkalaemia and decreased renal function (including acute renal failure) have been reported in susceptible individuals, especially if combining medicinal products that affect this system (see section 5.1).
Croatian: Hipotenzija, sinkopa, moždani udar, hiperkalemija i smanjena bubrežna funkcija (uključujući akutno zatajenje bubrega) zabilježeni su u osjetljivih pojedinaca, osobito ako su se kombinirali lijekovi koji utječu na taj sustav (vidjeti dio 5.1).
English: For products containing candesartan, the existing product information shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below
Croatian: Za lijekove koji sadrže kandesartan postojeće informacije o lijeku se trebaju izmjeniti (umetanjem, zamjenom ili brisanjem teksta prema potrebi) da odražavaju dogovoreni tekst kao što je predviđeno u nastavku
English: For angiotensin II receptor blockers with wording in section 4.1 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Croatian: Za blokatore angiotenzin II receptora s tekstom u dijelu 4.1 u kojem se navodi da se mogu primjenjivati sami ili u kombinaciji s drugim antihipertenzivnim lijekovima, potrebno je dodati sljedeću referencu: “(vidjeti dijelove 4.3, 4.4, 4.5 i 5.1)”.
English: The following wording should be incorporated in this section:
Croatian: U ovom dijelu potrebno je navesti sljedeći tekst:
English: For all ACE-inhibitors with wording in section 4.1 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Croatian: Za sve ACE inhibitore s tekstom u dijelu 4.1 u kojem se navodi da se mogu primjenjivati sami ili u kombinaciji s drugim antihipertenzivnim lijekovima, potrebno je dodati sljedeću referencu: “(vidjeti dijelove 4.3, 4.4, 4.5 i 5.1)”.
English: For all ACE-inhibitors with wording in section 4.2 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Croatian: Za sve ACE inhibitore s tekstom u dijelu 4.2 u kojem se navodi da se mogu primjenjivati sami ili u kombinaciji s drugim antihipertenzivnim lijekovima, potrebno je dodati sljedeću referencu: “(vidjeti dijelove 4.3, 4.4, 4.5 i 5.1)”.
English: For valsartan-containing products with wording in section 4.2 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Croatian: Za lijekove koji sadrže valsartan s tekstom u dijelu 4.2 u kojem se navodi da se mogu primjenjivati sami ili u kombinaciji s drugim antihipertenzivnim lijekovima, potrebno je dodati sljedeću referencu: “(vidjeti dijelove 4.3, 4.4, 4.5 i 5.1)”.
English: For valsartan-containing products with wording in section 4.1 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Croatian: Za lijekove koji sadrže valsartan s tekstom u dijelu 4.1 u kojem se navodi da se mogu primjenjivati sami ili u kombinaciji s drugim antihipertenzivnim lijekovima, potrebno je dodati sljedeću referencu: “(vidjeti dijelove 4.3, 4.4, 4.5 i 5.1)”.
English: “Your doctor may need to change your dose and/or to take other precautions: If you are taking an angiotensin II receptor blocker (ARB) or aliskiren (see also information under the headings “Do not <take> <use> X” and “Warnings and precautions”)”
Croatian: Ako uzimate neki blokator angiotenzin II receptora (ARB) ili aliskiren (vidjeti također informacije pod naslovima “Nemojte <uzimati> <primjenjivati> X” i “Upozorenja i mjere opreza”).”
English: The following wording should be incorporated in the “Heart failure” section:
Croatian: “Doziranje kod zatajenja srca”:
English: For candesartan-containing products with wording in section 4.1 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Croatian: Za lijekove koji sadrže kandesartan s tekstom u dijelu 4.1 u kojem se navodi da se mogu primjenjivati sami ili u kombinaciji s drugim antihipertenzivnim lijekovima, potrebno je dodati sljedeću referencu: “(vidjeti dijelove 4.3, 4.4, 4.5 i 5.1)”.
English: Section 4.2 - Posology and method of administration For angiotensin II receptor blockers with wording in section 4.2 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Croatian: Za blokatore angiotenzin II receptora s tekstom u dijelu 4.2 u kojem se navodi da se mogu primjenjivati sami ili u kombinaciji s drugim antihipertenzivnim lijekovima, potrebno je dodati sljedeću referencu: “(vidjeti dijelove 4.3, 4.4, 4.5 i 5.1)”.
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, Marketing Authorisation Holders in the Member States
Croatian: Popis naziva, farmaceutskih oblika, jačina lijekova, puteva primjene, nositelja odobrenja u državama članicama
English: Box 1711
Croatian: P.O. Box 1711
English: Modified-release capsule, hard
Croatian: Kapsula s prilagođenim oslobađanjem, tvrda
English: C. G. Papaloisou Ltd. Office address:
Croatian: C. G. Papaloisou Ltd.
English: Coated tablet
Croatian: Obložena tableta
English: P.O.
Croatian: Prilog I.
English: Modified-release tablet
Croatian: Tableta s prilagođenim oslobađanjem
English: Sarotex Retard 25 mg
Croatian: Saroten retard Tabs 75 mg
English: --1 Inactivated influenza A virus/human, strain A/Jena/VI5258/2009(H1N1)pdm09 ≥ 16 HU* *HU = haemagglutinating units
Croatian: --1 Inaktivirani virus gripe A/ljudski Soj: A/Jena/VI5258/2009(H1N1)pdm09 ≥ 16 HU*
English: Annex A
Croatian: Dodatak A
English: Packaging Content
Croatian: Put primjene Pakovanje Sastav Veličina pakovanja
English: EU (MA) Number Invented name
Croatian: Izmišljeno ime
English: ALMIRALL, S.A. Ronda General Mitre,
Croatian: Španjolska ALMIRALL, S.A. Ronda General Mitre,
English: Belgium Mylan BVBA/SPRL Terhulpsesteenweg 6A,
Croatian: Mylan BVBA/SPRL Terhulpsesteenweg 6A,
English: Weifa AS, Hausmannsgate 6, P.O.Box 9113
Croatian: Norveška Weifa AS, Hausmannsgate 6, P.O.Box 9113
English: Belgium Teva Pharma Belgium Laarstraat 16
Croatian: Teva Pharma Belgium Laarstraat 16
English: EG LABOLaboratoires EuroGenerics "Le Quintet"bâtiment A 12, rue Danjou
Croatian: EuroGenerics "Le Quintet"bâtiment A 12, rue Danjou
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the Member States
Croatian: Popis imena, farmaceutskih oblika, jačina lijekova, puteva primjene, nositelja odobrenja u zemljama članicama
English: Merck Medication Familiale
Croatian: Francuska Merck Medication Familiale
English: Unipharm JSC Traiko Stanoev str. № 3 + Sofia 1797
Croatian: Bugarska Unipharm JSC Traiko Stanoev str. № 3 + Sofia 1797
English: The Netherlands ratiopharm Nederland B.V.
Croatian: Nizozemska ratiopharm Nederland B.V.
English: 37, rue Saint-Romain 69379 Lyon Cedex 08 France
Croatian: 37, rue Saint-Romain 69379 Lyon Cedex 08
English: Meda Pharma (France) 25 boulevard de l'amiral bruix
Croatian: Francuska Meda Pharma (France) 25 boulevard de l'amiral bruix
English: NOVARTIS CONSUMER HEALTH, S.A.
Croatian: Španjolska NOVARTIS CONSUMER HEALTH, S.A.
English: Germany Berlin-Chemie AG Glienicker Weg 125
Croatian: Njemačka Berlin-Chemie AG Glienicker Weg 125
English: Sweden sanofi-aventis AB Box: 14142
Croatian: Švedska sanofi-aventis AB Box: 14142
English: Elaiapharm2881, Route des Crêtes
Croatian: Francuska Elaiapharm 2881, Route des Crêtes
English: Sweden Evolan Pharma AB Box: 120
Croatian: Evolan Pharma AB Box: 120
English: 69007 Lyon France
Croatian: 69007 Lyon
English: 08228 Tarrasa (Barcelona) Spain
Croatian: 08228 Tarrasa (Barcelona)
English: ITALFARMACO, S.A. San Rafael, 3
Croatian: Španjolska ITALFARMACO, S.A. San Rafael, 3
English: Pharmastra 2c, rue du marchal de lattre de tassigny
Croatian: Francuska Pharmastra 2c, rue du marchal de lattre de tassigny
English: Bega Nr. 4, TârguMureş, 540390
Croatian: Mureş, 540390
English: Societe Cilfa Developpement 20, Rue Jean Daudin 75015 - Paris France
Croatian: Francuska Societe Cilfa Developpement 20, Rue Jean Daudin 75015 - Paris
English: Belgium Sterop Laboratoires nv Avenue de Scheut 46
Croatian: Sterop Laboratoires nv Avenue de Scheut 46
English: S.C. Farmacom S.A. Str. Zizinului Nr. 112, 2200 Braşov,
Croatian: Rumunjska S.C. Farmacom S.A. Str. Zizinului Nr. 112, 2200 Braşov,
English: Gifrer Barbezat8 10, Rue Paul Bert Bp 165
Croatian: Francuska Gifrer Barbezat8 10, Rue Paul Bert Bp 165
English: Sweden Meda AB Box 906
Croatian: Meda AB Box 906
English: Sweden Recip AB Box: 906
Croatian: Recip AB Box: 906
English: Luxembourg Laboratoires SMB S.A. Rue de la Pastorale 26- 28 B 1080
Croatian: Luksemburg Laboratoires SMB S.A. Rue de la Pastorale 26- 28 B 1080
English: Luxembourg GlaxoSmithKline Consumer Healthcare S.A. Site Apollo avenue Pascal 2-6 B1300 Wavre
Croatian: Luksemburg GlaxoSmithKline Consumer Healthcare S.A. Site Apollo avenue Pascal 2-6 B1300 Wavre
English: 15, boulevard Charles de Gaulle
Croatian: Francuska Biogaran 15, boulevard Charles de Gaulle
English: Luxembourg Meda Pharma GmbH&Co.
Croatian: Luksemburg Meda Pharma GmbH&Co.
English: SW1V 2SA United Kingdom
Croatian: SW1V 2SA
English: Belgium Laboratoires SMB SA rue de la Pastorale 26
Croatian: Laboratoires SMB SA rue de la Pastorale 26
English: Germany Dr. R. Pfleger Chemische Fabrik GmbH
Croatian: Njemačka Dr. R. Pfleger Chemische Fabrik GmbH
English: Arrow Generiques 26, avenue Tony Garnier
Croatian: Francuska Arrow Generiques 26, avenue Tony
English: 2333 CR Leiden The Netherlands
Croatian: 2333 CR Leiden
English: Azur compositum SC Suppositorien suppository rectal use
Croatian: Azur compositum SC Suppositorien čepić rektalno
English: Luxembourg Bristol-Myers Squibb Belgium S.A. Avenue de Finlande, 8 B-1420
Croatian: Luksemburg Bristol-Myers Squibb Belgium S.A. Avenue de Finlande, 8 B-1420
English: ibuprofen + codeine Nurofen Plus
Croatian: ibuprofen + kodein Nurofen Plus
English: Denmark Amgros I/S, Dampfærgevej 22, DK-2100 København Ø, Denmark
Croatian: Amgros I/S, Dampfærgevej 22, DK-2100 København Ø, Danska kodein
English: S.C. TERAPIA S.A Str. Fabricii Nr.124, Cluj-Napoca, Judeţul Cluj, 400632
Croatian: Fabricii Nr.124, Cluj-Napoca, Judeţul Cluj, 400632
English: INTERNACIONAL, S.A. Gran Vía Carlos III, 94 08028 Barcelona Spain
Croatian: Španjolska FERRER INTERNACIONAL, S.A. Gran Vía Carlos III, 94 08028 Barcelona
English: Sanofi-Aventis France 1-13, Boulevard Romain Rolland
Croatian: France 1-13, Boulevard Romain Rolland
English: Nitrianska 100, Hlohovec 920 27 Slovak Republic codeine
Croatian: Nitrianska 100, Hlohovec 920 27 Republika Slovačka kodein
English: Algocod powder
Croatian: Algocod prašak
English: 032266 Bucureşti, Romania codeinum
Croatian: 032266 Bucureşti, Rumunjska kodein
English: LABORATORIOS ASOCIADOS NUPEL, S.L.
Croatian: Španjolska LABORATORIOS ASOCIADOS NUPEL, S.L.
English: Germany Merck Serono GmbH Alsfelder Str. 17
Croatian: Njemačka Merck Serono GmbH Alsfelder Str. 17
English: Ziduri între Vii nr.22, Bucureşti, sector 3, 023324
Croatian: Rumunjska S.C. SINTOFARM S.A.Str. Ziduri între Vii nr.22, Bucureşti, sector 3, 023324
English: Bristol Myers Squibb3, rue Joseph Monier 92500 RueilMalmaison
Croatian: Francuska Bristol Myers Squibb3, rue Joseph Monier 92500 Rueil
English: Str. Ştirbei Vodă Nr. 53-55, Sector 1, Bucureşti,
Croatian: Str. Ştirbei Vodă Nr. 53-55,
English: 49, avenue Georges Pompidou
Croatian: Francuska SANDOZ 49, avenue Georges Pompidou
English: Pelplińska 19 Starogard Gdański
Croatian: Farmaceutyczne POLPHARMA S.A. ul. Pelplińska 19 Starogard Gdański
English: Cod., suppositoria 400 mg 9.6 mg
Croatian: A.C. Cod., suppositoria 400 mg 9.6 mg
English: Luxembourg Mylan bvba/sprl Rozendal Businesspark Terhulpsesteenweg 6A B-1560 Hoeilaart Belgium
Croatian: Luksemburg Mylan bvba/sprl Rozendal Businesspark Terhulpsesteenweg 6A B-1560 Hoeilaart Belgija paracetamol/ kodeinfosfat
English: 75014 Paris France
Croatian: 75014 Paris
English: Germany MEDA Manufacturing GmbH
Croatian: Njemačka MEDA Manufacturing GmbH